Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina
-
Published:2023-11
Issue:
Volume:79
Page:104935
-
ISSN:2211-0348
-
Container-title:Multiple Sclerosis and Related Disorders
-
language:en
-
Short-container-title:Multiple Sclerosis and Related Disorders
Author:
Alonso Ricardo, Casas Magdalena, Lazaro Luciana, Liguori Nora Fernandez, Pita Cecilia, Cohen Leila, Rojas Juan Ignacio, Pappolla Agustín, Patrucco Liliana, Cristiano Edgardo, Burgos Marcos, Vrech Carlos, Piedrabuena Raul, Pablo Lopez, Deri Norma, Luetic Geraldine, Miguez Jimena, Cabrera Mariela, Martinez Alejandra, Zanga Gisela, Tkachuk Verónica, Tizio Santiago, Carnero Contentti Edgar, Knorre Eduardo, Leguizamon Felisa, Mainella Carolina, Nofal Pedro, Liwacki Susana, Hryb Javier, Menichini Maria, Pestchanker Claudia, Garcea Orlando, Silva BereniceORCID
Subject
Neurology (clinical),Neurology,General Medicine
Reference36 articles.
1. Usage trend of oral drugs for multiple sclerosis patients in Argentina;Alonso;Mult. Scler. Relat. Disord.,2021 2. Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America;Alonso;Mult. Scler. Relat. Disord.,2022 3. Baynton, E., 2022. A new era in multiple sclerosis. Global Therapy Monitors, Ipsos. https://www.ipsos.com/sites/default/files/ct/publication/documents/2022-08/Ipsos_A%20New%20Era%20In%20Multiple%20Sclerosis_July%202022.pdf; Accessed 05 July 2022. 4. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis;Boremalm;Eur. J. Neurol.,2019 5. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis;Brown;JAMA,2019
|
|